Gene therapy to regenerate heart tissue in patients with heart failure
Official title: Triple Gene Therapy for Ischemic Heart Failure
Funded at Baylor College of Medicine · NIH-11040424 · Data updated 2026-11-12
This study is exploring a new way to help people with ischemic heart failure by using a mix of three gene therapies that aim to heal the heart and improve its function, and patients may have the chance to participate in trials to see how well this treatment works.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | March 18, 2025 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $560,000 |
| NIH project number | 1R61HL177472-01 |
| Project ID | NIH-11040424 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults over 21 years old who have been diagnosed with ischemic heart failure.
✕Less likely to help
Patients with heart failure due to non-ischemic causes or those who are not eligible for gene therapy may not benefit from this research.
What this research studies
This research investigates a novel approach to treat ischemic heart failure by using a combination of three gene therapies aimed at regenerating heart tissue. The therapies focus on inducing the proliferation of heart cells, reprogramming existing fibroblasts into heart cells, and enhancing blood vessel formation in the heart. By testing these therapies together, the research aims to provide a comprehensive solution to restore heart function. Patients may be involved in clinical trials to evaluate the safety and effectiveness of this combined treatment.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that restores heart function in patients suffering from ischemic heart failure.
How similar studies have gone: Previous studies have shown promising results with individual gene therapies for heart regeneration, but this combined approach is novel and has not been extensively tested.
Where this research is happening
-
Baylor College of Medicine
Houston, United States Active
Researchers
- Principal investigator: Mohamed, Tamer M a — Baylor College of Medicine
- Study coordinator: Mohamed, Tamer M a
Related research
Other NIH-funded projects on the same topics.
-
AI-supported heart failure diagnosis and management in Rwanda
Aiming to help people with suspected heart failure in Rwanda get faster, more accurate diagnoses and better care using AI-guided ultrasound and care protocols.
-
AI-assisted heart failure diagnosis in Rwanda using focused ultrasound
An NIH-funded project will test whether AI-enhanced, easy-to-use heart ultrasound can help non-experts diagnose and manage heart failure in Rwanda.
-
HF endotypes in heart failure using ethical multi-modal AI and molecular data
A patient-friendly project that uses advanced AI and multiple kinds of health data to identify distinct heart failure subtypes that could guide personalized care.
-
Triple gene therapy approach to heal the heart after a heart attack
A new therapy combines three genetic approaches delivered by a virus to help the heart heal after a heart attack.
-
Digital-first heart failure care delivery in Uganda
A targeted program in Uganda tests a digital care plan to help people with heart failure manage their symptoms at home.
-
Digital-first heart failure care delivery in Uganda
A study to test digital self-care tools to help people with heart failure in Uganda manage symptoms and stay healthier.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.